Recombinant XXXX therapy increases erythrocyte expression of complement regulatory proteins.

@entity1 @entity3432 @entity417 @entity1009 @entity1307 @entity5301 @entity2142 @entity9819
BACKGROUND: One of the complications of hemodialysis (HD) therapy is @entity417 caused by @entity1307 ( @entity1307 ) deficiency. Recombinant @entity1307 ( @entity5301 ) has been used routinely as a supplemental treatment. Erythrocyte expression of the complement regulatory proteins @entity9819 ( @entity9819 ) and @entity1009 restricts complement activation and inhibits @entity2142 . We hypothesized that the efficacy of @entity5301 treatment may be caused in part by the ability of @entity5301 to increase erythrocyte expression of @entity9819 and @entity1009 . METHODS: @entity9819 , @entity1009 , and @entity3432 ( @entity3432 ) levels were analyzed for a group of 95 HD @entity1 and compared with those of a control group. To evaluate effects of discontinuation of @entity5301 therapy, @entity5301 therapy was stopped for 12 HD @entity1 until hematocrits decreased to less than 25%. @entity9819 and @entity1009 levels then were reanalyzed. RESULTS: In the 95 HD @entity1 , three factors correlated significantly: @entity9819 and @entity1009 (r = 0.642), @entity9819 and @entity3432 (r = 0.503), and @entity1009 and @entity3432 (r = 0.324), whereas no correlations were found in the group of 42 healthy controls. In the experiment in which @entity5301 therapy was discontinued, 8 of 12 @entity1 reached the defined level of @entity417 4 to 7 weeks after @entity5301 treatment had been withheld. Both @entity9819 and @entity1009 levels decreased significantly after discontinuation of @entity5301 therapy (P < 0.01). @entity9819 and @entity1009 levels increased in all 8 @entity1 after @entity5301 treatment was reinitiated (P < 0.01), and @entity3432 levels increased in 5 of 8 @entity1 . Four of 12 @entity1 showed no evidence of @entity417 after discontinuation of @entity5301 treatment. In these @entity1 , @entity9819 , @entity1009 , and @entity3432 levels did not change before or after withholding @entity5301 therapy. CONCLUSION: One of the mechanisms mediating the efficacy of @entity1307 therapy is increased @entity9819 and @entity1009 expression.
